Search

Objective To explore the effect of 1-year non-stop alendronate treatment on the quality of life of postmenopausal osteoporotic patients. Methods A total of 265 patients with postmenopausal osteoporosis who were admitted to our hospital from May 2015 to December 2016 and received alendronate treatment of 70 mg per week were selected. During the 1-year observation period from the start of selection, the quality of life at baseline and 3, 6, and 12 months after enrollment was evaluated using European QOL 5 dimensional (EQ-5D) and Japan Osteoporosis Quality of Life Questionnaire (JOQOL). Results In 265 evaluable patients, a significant improvement in quality of life was observed from 3 months after enrollment and remained constant throughout the 1-year observation period. After treatment both EQ-5D and JOQOL were significantly improved (P<0． 05) within 1 year of treatment. Factors identified as causing changes in QOL included: fractures within one year before enrollment, skeletal deformities, osteoarthritis, use of active vitamin D3, age based on JOQOL, and vertebral deformities. The result showed that the patient's perception of the therapeutic effect, such as pain improvement, contributed to the continuation of the treatment. Patients with osteoporosis knew that once a week of bisphosphonate treatment for sustainable treatment, regardless of the complications of exercise disorders, could significantly improve the quality of life and encouraged them to continue treatment. Conclusion Continuous bisphosphonates treatment improves quality of life even in patients with motor diseases. The use of active vitamin D3 also helps to further improve the quality of life. [ABSTRACT FROM AUTHOR]